DXR Daxor Corporation logo

DXR Daxor Corporation

Healthcare
$10.82+0.00%ClosedMarket Cap: $54.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

4.91

PEG

0.06

P/B

1.19

P/S

362.98

EV/EBITDA

5.72

DCF Value

$-0.03

FCF Yield

0.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

-57.5%

Operating Margin

6174.2%

Net Margin

6105.3%

ROE

22.5%

ROA

19.9%

ROIC

20.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$131.8K$9.5M$
FY null$503.4K$9.2M$
Q2 null$18.3K$-369.7K$
Q4 null$695.3K$2.2M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$23.00

Target (Median)

$23.00

Target Range

$23.00 - $23.00

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Feldschuh Michael Richarddirector, officer: Chief Executive Officer
BuyFri Apr 10
Michel Robert Jofficer: Chief Financial Officer
BuyTue Mar 31
Jefferies Johnofficer: Chief Medical Officer
BuyTue Mar 24
Jefferies Johnofficer: Chief Medical Officer
BuyTue Mar 24
Michel Robert Jofficer: Chief Financial Officer
BuyThu Dec 11

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

0.29

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Peers